The Circulating Cell-free Genome Atlas Study

Status unconfirmed

Conditions studied: Neoplasms, Cancer

In brief

GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from participants with a new diagnosis of cancer (blood and tumor tissue) and from participants who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer participants and to develop models for distinguishing cancer from non-cancer.

Key facts

Study ID
NCT02889978
Run by
GRAIL, Inc.
People needed
15254
Starts
2016-08-04
Expected to finish
2024-03-01
Last updated by the study team
2023-09-13

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.